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Objective. To estimate the net health beneﬁts of pegaptanib and ranibizumab by considering the impact of visual acuity and
unintended eﬀects (cardiovascular and hemorrhagic events) on quality-of-life among persons with neovascular age-related
macular degeneration. Methods. We designed a probabilistic decision-analytic model using published data. It employed 17 visual
health states and three for unintended eﬀects. We calculated incremental net health beneﬁts by subtracting the harms of each
medication from the beneﬁt using the quality-adjusted life year (QALY). Results. In a hypothetical cohort of 1,000 75-year olds
with new-onset bilateral age-related macular degeneration followed for ten years, the mean QALYs per patient is 3.7 for usual care,
4.2forpegaptanib,and4.3forranibizumab.Netbeneﬁtsdeclinewithincreasingbaselineratesofunintendedeﬀects.Interpretation.
Net health beneﬁts present a quantitative, potentially useful tool to assist patients and ophthalmologists in balancing the beneﬁts
and harms of interventions for age-related macular degeneration.
Copyright © 2009 Adrian R. Levy et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
In response to shifting expectations from the general public,
the regulation of medications is undergoing important
changes in Canada and abroad including by the United
States’ Food and Drug Administration and the European
Medicines Agency. In this country, Health Canada has
introduced the Progressive Licensing Project in order “to
develop a modern, integrated approach to the regulation
of pharmaceuticals and biologics that can be implemented
throughout the lifecycle of these drugs” [1]. One of the
underlying principles is that joint evaluation of the risks
and beneﬁts of a medication is to occur throughout its
lifecycle and thereby extends the current system which
focuses regulatory approval on the premarketing phase.
There are formidable hurdles to the proposed new system
including the development of metrics that quantitatively
incorporate both risks and beneﬁts. One method that
has been proposed is the use of decision models that
capture all relevant intended and unintended eﬀects [2,
3]. One advantage of decision models is that preferences
for diﬀerent health states can be explicitly incorporated
into the decision-making process. In this study, we present
the joint estimation of risks and beneﬁts among two
intravitreal vascular endothelial growth factor (VEGF)
inhibitors recently licensed in Canada and other major
markets for treating neovascular age-related macular degen-
eration.2 Journal of Ophthalmology
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Figure 1: Structure of the risk-beneﬁt decision model.
Age-related macular degeneration is a progressive degen-
eration of the macula that occurs in up to one-third of
persons aged 65 years and over [4]. Up to 15% of suﬀerers
develop the neovascular form in which the development
of choroidal neovascularization (growth of abnormal blood
vessels), if untreated, progresses to severe central visual loss,
macular scarring, and legal blindness [5]. In recent years two
intravitreal VEGF inhibitors have been marketed and put
in use in Canada and internationally: in 2004, pegaptanib
(Macugen), a VEGF165-speciﬁc RNA aptamer [6], and in
2006 ranibizumab (Lucentis) [7, 8], a nonspeciﬁc pan-
VEGF antibody. While both VEGF inhibitors were shown
to be better than usual care (no treatment or photodynamic
therapy with verteporﬁn, if clinically indicated) in slowing
the progression of visual loss in the registration trials, the
magnitude of beneﬁt was greater in trials of ranibizumab
(ANCHOR[7,8])thaninthoseofpegaptanib(VISION[6]).
No head-to-head trials have been published.
VEGF inhibitors have the potential to aﬀect the cardio-
vascular system, leading to concerns about the possibility of
unintended cardiovascular (particularly, arterial thrombotic
events) and hemorrhagic adverse drug reactions [9]. The
degree of cardiovascular risk due to VEGF inhibitors is likely
todependonavarietyoffactorsincludingtheconcentrations
in the systemic circulation, half-life, and breadth of activity.
Of note, there is evidence that persons with neovascular age-
related macular degeneration may already be at elevated risk
of cardiovascular disease [10, 11].
The objective of this study was to estimate the net
health beneﬁts of intravitreal VEGF inhibitors by jointly
considering the impact on duration and quality of life of
intendedandunintendedeﬀectsamongahypotheticalgroup
of patients with bilateral neovascular age-related macular
degeneration.Weundertookthresholdanalysestodetermine
the levels of cardiovascular and hemorrhagic risks at which
greater eﬃcacy may be oﬀset by greater risks of unintended
eﬀects.
2. Methods
We designed a probabilistic decision analytic model [12]i n
which the incremental net health beneﬁt was calculated by
subtracting the net harms in each treatment from the beneﬁt
usingthequality-adjustedlifeyear(QALY)[13]asacommon
metric. The target population was adults aged 75 years with
new onset neovascular age-related macular degeneration in
the second eye. Hypothetical subjects were entered into the
model having the distribution of visual acuity reported in
the VISION trial [6] .Th e s es u b j ect sh adam e a nvi s u a lac u i ty
of 53 ETDRS letters (Snellen chart 20/63) and an estimated
mean baseline health-related quality of life utility of 0.72.
Baseline characteristics of the trial samples on whom the
hypothetical cohort is based are presented in the Appendix.
The cycle length (or equivalently, the duration over which an
individual remained in the same health state before having
the opportunity to transition to another) was one year and
t h em o d e lw a sr u nf o rt e ny e a r s .
The Markov model employed 17 health states for classi-
fying the intended eﬀects of treatment, which were based on
EarlyTreatmentofDiabeticRetinopathyStudy(ETDRS)log-
MAR visual acuity categories (Figure 1)w h i c hr a n g e df r o m
20/20 (perfect vision) to 20/800 (severe visual impairment;
the cutoﬀ for legal blindness is 20/200). During each cycle,Journal of Ophthalmology 3
Table 1: Model inputs, intended and unintended eﬀects.
Intended Eﬀects Pegaptanib
(n = 294)1n (%)
Ranibizumab
(n = 379)2n (%)
UC Combined
(n = 677)3n (%)
Loss of ≥6 lines ETDRS VA 28 (9.5) 3 (0.8) 118 (39.9)
Loss of ≥3b u t<6 lines ETDRS VA 60 (20.4) 15 (4.0) 153 (51.7)
Loss of >0b u t<3 lines ETDRS VA 108 (36.7) 83 (21.9) 227 (76.7)
Gain of ≥0b u t<3 lines ETDRS VA 80 (27.2) 140 (36.9) 153 (51.7)
Gain of ≥3 lines ETDRS VA 18 (6.1) 138 (36.4) 26 (8.8)
Unintended Eﬀects
Nonfatal MI, % (SE) 0.3 (0.378) 1.1 (0.525) 0.6 (0.295)
RR (95% CI) Nonfatal MI, versus UC 0.5 (0.0–5.5) 2.0 (0.4–10.9) —
Nonfatal CVA, % (SE) 1.0 (0.586) 1.1 (0.525) 0.4 (0.255)
R R( 9 5 %C I )N o n f a t a lC V A ,v e r s u sU C 3.0 (0.3–28.9) 2.0 (0.4–10.9) —
Nonfatal severe NOH, % (SE) 1.0 (0.653) 1.5 (0.614) 0.6 (0.295)
RR (95% CI) Nonfatal severe NOH, versus UC 1.0 (0.2–4.9) 5.5 (0.7–46.3) —
1From VISION Study [6] of 0.3mg pegaptanib, and VISION-study safety and eﬃcacy summaries provided by Pﬁzer Inc.
2Pooled estimates from MARINA and ANCHOR [7, 8] studies of 0.5mg ranibizumab.
3Pooled estimates from the control arms of the VISION [6], ANCHOR and MARINA [7, 8] studies.
ETDRS VA: Early Treatment of Diabetic Retinopathy Study visual acuity; MI: myocardial infarction; SE-standard error; 95%CI: 95% conﬁdence interval; UC:
Usual care; NOH: nonocular hemorrhage.
subjects could stay in the same state, improve to a better
state, or deteriorate to a worse state, and could experience an
unintended eﬀect (severe nonocular hemorrhage, nonfatal
myocardial infarction (MI), or nonfatal cerebrovascular
accident (CVA)), or die (from nonocular hemorrhage, MI,
CVA, or from other cause). Transition probabilities for
intended and unintended eﬀects were annualized based
on the rates reported in the ﬁrst year of the registration
trials for pegaptanib (dose 0.3mg) or ranibizumab (dose
0.5mg). Unintended eﬀects from the VISION study of
pegaptanib-treated patients [6] were categorized according
to the MARINA and ANCHOR study criteria [7, 8]. Subjects
who did not die or experience a nonfatal CVA entered the
next cycle in the same intended eﬀect health state; it was
assumed that subjects recovered fully after experiencing a
nonocular hemorrhage or MI. Subjects who experienced a
CVA were assumed to remain in that health state until death.
Some proportion of subjects transited to the death state
during each cycle, based on all-cause mortality rates from
2002 Canadian life tables [14–16]. As the proportions of
fatal MI and CVA in the registration trials were low (<1.0%
in all trials; 0.8% among ranibizumab-treated patients
(threeevents),0.7%amongpegaptanib-treatedpatients(two
events), and 0.3% among usual care-treated patients (two
events)), these events were accounted for within all-cause
mortality rates. The beneﬁts of treatment were measured by
the change in visual acuity in the treated eye observed at
the end of one year in the registration trials of pegaptanib
and ranibizumab (Table 1 and Appendix) [6–8]. Unintended
eﬀects of treatment included ranibizumab treatment in the
ANCHOR/MARINA trials was associated with relative risks
(RR; compared to usual care) of 1.5 (loss of <3 lines of
VA), 2.2 (APTC events) and 5.5 (nonocular hemorrhage).
Pegaptanib treatment in the VISION Study was associated
with RRs (compared to usual care) of 1.2 (loss of <3 lines of
VA), 1.5 (APTC events), and 0.8 (nonocular hemorrhage).
In the registration trials, the beneﬁts in terms of visual
acuity were stronger for ranibizumab than for pegaptanib:
95% of ranibizumab-treated patients experienced less than
three lines of ETDRS visual acuity loss, whereas 70% of
pegaptanib-treated patients experienced the same outcome.
As the registration trials were of limited duration, an
assumption was required about the treatment eﬃcacy after
one year. In the base case, the absolute value of the treatment
beneﬁt observed in the ﬁrst year of the trials (intention-to-
treat) was assumed to continue without attenuation in the
active treatment arms. This assumption was supported by
the minimal change observed amongst those who remained
on treatment in open-label follow-ups of the VISION (−0.6
letters) [17] and MARINA (−0.6 letters [8]) trials.
Cardiovascular events (as deﬁned by the Anti-Platelets
Trialists’ Collaborative (APTC) [18]) and severe nonocular
hemorrhage. In threshold analyses designed to simulate
populations at diﬀering baseline risk of cardiovascular
or nonocular hemorrhagic events, the absolute risk was
assumed to increase linearly with baseline risk, while the
relative risk of experiencing an event (compared to usual
care) remained constant.
Utilities for health states classiﬁed by visual acuity levels
were obtained from a published study of patients with
ophthalmic disease and were based on Snellen visual acuity
in the better-seeing eye [19, 20]. Utilities for unintended
eﬀects were from patients suﬀering the event of interest
(Table 2)[ 21–25] .W ea s s u m e dt h a tM Ia n dN O He v e n t s
occurred at the beginning of the year, and the utility
decrement associated with these events was applied for one
model cycle. We assumed the utility decrement associated
with CVA to be permanent and apply for the duration
of an individual’s life (as all trial CVAs were severe). We
assumed multiplicative eﬀects on quality of life for persons4 Journal of Ophthalmology
Table 2: Utilities, intended and unintended eﬀects.
Mean Utility (95% CI)
Intended Eﬀects1
BCVA in the better-seeing eye
20/20 0.92 (0.87–0.97)
20/25 0.87 (0.82–0.92)
20/32 0.84 (0.79–0.89)
20/40 0.80 (0.74–0.86)
20/50 0.77 (0.70–0.84)
20/63 0.74 (0.67–0.81)
20/80 0.74 (0.67–0.81)
20/100 0.67 (0.57–0.77)
20/125 0.67 (0.57–0.77)
20/160 0.66 (0.55–0.77)
20/200 0.66 (0.55–0.77)
20/250 0.63 (0.54–0.72)
20/320 0.63 (0.54–0.72)
20/400 0.54 (0.43–0.65)
20/500 0.54 (0.43–0.65)
20/640 0.54 (0.43–0.65)
20/800 0.52 (0.36–0.68)
Unintended Eﬀects
CVA2 0.52 (0.42–0.62)
MI3 0.88 (0.84–0.93)
NOH4 0.81 (0.74–0.87)
1From Brown et al. [19], originally referenced in Brown 1999 [20].
2Calculated based on utility decrement associated with a major stroke, from
meta-analysis by Tengs and Lin 2003 [21].
3F r o mT s e v a te ta l .[ 22].
4Based on 3-month utility for a severe gastrointestinal hemorrhage
requiring medical intervention, from Maetzel et al. 2001 [23]. Patients were
assumed to return to full health for the duration of the cycle.
95% CI: 95% conﬁdence interval; BCVA: best-corrected visual acuity;
CVA: cerebrovascular accident; MI: myocardial infarction; NOH: nonocular
hemorrhage.
undergoing more than one unintended health event. This
assumption was consistent with the results of another study
[26] and avoided the possibility of negative utilities (which
would be interpreted as states worse than death, without
empirical data). In sensitivity analysis we also examined the
eﬀect of using new utility data based on ETDRS (rather
than Snellen) visual acuity categories (poster presentation
Association for Research in Vision and Ophthalmology 2009
annual meeting) [27].
2.1. Analyses. Q A L Y sw e r eu s e da sac o m m o nm e t r i ct o
capture the joint impact of changes in visual acuity and
unintended eﬀects. The incremental net health beneﬁts after
ten years were estimated by subtracting the net QALY loss
from experiencing unintended eﬀects, from the net QALYs
associated with intended eﬀects. All QALYs were discounted
at 5% annually to reﬂect time preference (that costs and
beneﬁts that occur in the future are worth less than those
currently available) [28].
Probabilisticsensitivityanalysiswasundertakentoexam-
ine the robustness of the results by incorporating the
joint uncertainty around the estimates of intended and
unintended eﬀects and utilities [29]. A beta distribution was
applied torandomly generateutility valuesandadverse event
probabilities. The method of moments was used to convert
empirically calculated means and standard deviations to
parameters of the beta distribution [30]. The Dirichlet
distribution was applied to generate fully probabilistic
transition matrices for the VEGF inhibitor treatments [29,
30]. Two alternative scenarios were incorporated to examine
the impact of diﬀerent assumptions about the beneﬁts
of treatment after 12 months. In the ﬁrst, the transition
probabilities following the ﬁrst year of treatment remained
constant with patients continuing to gain or lose vision at
the same rate as during the trial period. Patients therefore
continued accruing treatment beneﬁt for the duration of the
time horizon of the model. In the second, the treatment
beneﬁt was assumed to drop to zero after the ﬁrst year of
treatment and the transition probabilities were those of the
usual care group.
Background rates of cardiovascular and hemorrhagic
eventsfromtheusualcaregroup(Table 1)wereincorporated
intothebasecase.Toestimateincrementalnethealthbeneﬁts
in populations at diﬀering underlying risks of unintended
eﬀects, threshold analyses were undertaken for populations
at diﬀering baseline risks of cardiovascular events and severe
nonocular hemorrhage. Increased baseline risks of cardio-
vascular events up to 2% annual mortality were considered.
Increased baseline risks of severe nonocular hemorrhage up
to 5% annually were also considered.
The impact of diﬀerent discount rates from 0% to 7%
[31] was examined in a one-way sensitivity analysis. We also
examined ﬁve-year and lifetime time horizons. All model
results represent the mean values from 1,000 probabilistic
simulations. Point estimates of the net health beneﬁt are
presented with 95% conﬁdence intervals (95% CI) for the
main results. The model was developed in Microsoft Excel
2007 for Windows and is available from the authors upon
request.
3. Results
In a hypothetical cohort of 1,000 patients with new onset
bilateral neovascular age-related macular degeneration fol-
lowed for ten years, the mean number of QALYs was 3.7
(95% CI, 3.5–4.0) for usual care, 4.3 (95% CI, 4.1–4.4) for
pegaptanib, and 4.4 (95% CI, 4.2–4.5) for ranibizumab. Net
health beneﬁts declined with increasing age at treatment
initiation, from approximately 5.0 (pegaptanib; 4.8–5.2) or
5.1 (ranibizumab; 4.9–5.2) QALYs for patients aged 65 years,
to 2.9 (pegaptanib; 2.8–3.0) or 3.0 (ranibizumab; 2.8–3.1)
for patients aged 85 years (Figure 2). Net health beneﬁts, and
incremental net health beneﬁts, are presented in Table 3.
As the increased annual risk of cardiovascular events
increased up to 2%, the decline in beneﬁt in pegaptanib-
treated patients was greater than that seen in ranibizumab-
treated patients (to 4.2 versus 4.3 QALYs, resp.; Figure 3).
TheoppositetrendwasnotedwhentheannualincreasedriskJournal of Ophthalmology 5
Table 3: Net health beneﬁts (with 95% CI), and incremental net health beneﬁts, of VEGF inhibitor treatment in NV-AMD patients, by age
at treatment initiation (in quality-adjusted life years).
Net Health Beneﬁt (95% CI)
Age 65 y Age 75 y Age 85 y
Ranibizumab 5.06 (4.87–5.23) 4.36 (4.19–4.52) 2.97 (2.85–3.08)
Pegaptanib 4.98 (4.80–5.17) 4.29 (4.14–4.45) 2.93 (2.81–3.03)
UC 4.31 (4.00–4.60) 3.74 (3.48–3.98) 2.59 (2.44–2.75)
Incremental Net Health Beneﬁt
Age 65 y Age 75 y Age 85 y
Ranibizumab versus Pegaptanib 0.07 (0.01–0.14) 0.06 (0.01–0.12) 0.04 (0.01–0.08)
Pegaptanib versus UC 0.68 (0.40–0.95) 0.56 (0.34–0.77) 0.34 (0.21–0.47)
Ranibizumab versus UC 0.75 (0.45–1.04) 0.62 (0.38–0.86) 0.38 (0.24–0.53)
95% CI = 95% conﬁdence interval; UC = Usual care; y = years.
Net health beneﬁts were calculated by subtracting the net harms in each treatment from the beneﬁt using the quality-adjusted life year as a common metric.
Incremental net health beneﬁts were calculated by subtracting the net health beneﬁts of two of the treatment arms.
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Figure 2: Net health beneﬁts accruing to patients with neovascular
age-related macular degeneration when using vascular endothelial
growth factor inhibitors according to age (years) at treatment
initiation.
of nonocular hemorrhagic events was increased to 5%; the
net health beneﬁt declined for ranibizumab-treated patients
(to 4.1 QALYs), while the net health beneﬁt for pegaptanib-
treated patients remained the same (4.3 QALYs; Figure 4).
The impact of varying the assumptions regarding dura-
tion and magnitude of treatment beneﬁts indicated that
ranibizumab proﬀered the greatest net health beneﬁts under
the assumption that all patients continued gaining or losing
visionatthesameratebeyondthe1-yeardurationofthetrial
data (Table 4). Assuming that all treatment beneﬁts dropped
to zero after one year of treatment duration resulted in
only slightly positive net health beneﬁts among both groups
treated with a VEGF inhibitor.
When the model’s time horizon was varied, the relative
diﬀerence between the treatment arms was maintained,
although the absolute value of mean QALYs per participant
increased with the increasing time horizon of the model.
When the utility values to quality-adjust life expectancy
were varied from those based on Snellen visual acuity
categories to ETDRS, the relative diﬀerence between the
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Figure 3: Net health beneﬁts accruing to patients with neovascular
age-related macular degeneration when using vascular endothelial
growthfactorinhibitorsaccordingtoannualriskofacardiovascular
(CV) event.
treatment arms was maintained, although the absolute value
of mean QALYs per participant increased (Table 5).
4. Discussion
Using a decision-analytic framework and data from the
literature, we derived a single reproducible metric that
captured intended and unintended eﬀects of treatments
and incorporated quality of life weights. In this study,
we modeled the long-term net health beneﬁts of VEGF
inhibitors among patients with bilateral neovascular age-
related macular degeneration. Under a realistic assumption
that beneﬁts of treatment extended beyond the observed
duration of the trials, both pegaptanib and ranibizumab
oﬀered positive net health beneﬁts. Based on the results
of the registration trials, there is widespread perception
among ophthalmologists treating persons with neovascular
age-related macular degeneration that ranibizumab is more
eﬃcacious than pegaptanib. As in the registration trials,
we projected that the absolute beneﬁts were greater in6 Journal of Ophthalmology
Table 4: Mean quality-adjusted life years associated with alternate intended eﬀects scenarios incorporated over the duration of the model.
Net Health Beneﬁt
Base Case Scenario 1 Scenario 2
Ranibizumab 4.36 (4.19–4.52) 4.51 (4.34–4.69) 3.81 (3.60–4.03)
Pegaptanib 4.29 (4.14–4.45) 4.00 (3.81–4.17) 3.79 (3.57–4.02)
Scenario 1: Transition probabilities following the ﬁrst year of treatment remained constant, with patients continuing to gain or lose vision at the same rate as
during the trial period. Patients therefore continue accruing treatment beneﬁt for the duration of the time horizon of the model.
Scenario 2: Treatment beneﬁt was assumed to drop to zero after the ﬁrst year of treatment and the transition probabilities were those of the usual care group.
Net health beneﬁts were calculated by subtracting the net harms in each treatment from the beneﬁt using the quality-adjusted life year as a common metric.
Table 5: Net health beneﬁts, and incremental net health beneﬁts, in quality-adjusted life years, of VEGF inhibitor treatment in NV-AMD
patients, incorporating utility values based on ETDRS visual acuity categories.
Net Health Beneﬁt
Age 65 y Age 75 y Age 85 y
Ranibizumab 5.99 (5.90–6.09) 5.15 (5.07–5.23) 3.51 (3.46–3.57)
Pegaptanib 5.89 (5.79–5.99) 5.07 (4.99–5.15) 3.46 (3.40–3.51)
UC 5.26 (5.10–5.41) 4.54 (4.42–4.67) 3.13 (3.05–3.22)
Incremental Net Health Beneﬁt
Age 65 y Age 75 y Age 85 y
Ranibizumab versus Pegaptanib 0.09 (0.03–0.16) 0.08 (0.03–0.14) 0.06 (0.02–0.09)
Pegaptanib versus UC 0.64 (0.50–0.77) 0.53 (0.42–0.64) 0.32 (0.25–0.39)
Ranibizumab versus UC 0.73 (0.59–0.87) 0.61 (0.48–0.74) 0.38 (0.30–0.45)
UC = Usual care; y = years
Net health beneﬁts were calculated by subtracting the net harms in each treatment from the beneﬁt using the quality-adjusted life year as a common metric.
Incremental net health beneﬁts were calculated by subtracting the net health beneﬁts of two of the treatment arms.
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Figure 4: Net health beneﬁts accruing to patients with neovascular
age-related macular degeneration when using vascular endothelial
growth factor inhibitors according to annual risk of a nonocular
hemorrhagic (NOH) event.
ranibizumab-treated patients. However, when also account-
ing for unintended eﬀects, the mean diﬀerence between the
two treatments diminished, to 100 QALYs per 1,000 subjects
over a ten year time horizon. There are two potentially
nonexclusive reasons for the narrowing of diﬀerence: ﬁrst,
the trials of ranibizumab enrolled more patients with
predominantly classic subfoveal lesions, the natural history
of which are more aggressive. Predominantly classic lesions
may therefore appear to respond better to treatment [32,33],
including to VEGF inhibition, than other choroidal neovas-
cularization subtypes. Second, in all three registration trials,
approximately three-quarters of subjects had treatment-
eye visual acuities upon enrollment of between 20/40 and
20/200, corresponding to utilities between 0.80 and 0.66.
Even with apparently large diﬀerences in relative beneﬁts
in the number of patients experiencing less than three
lines of vision loss, the potential gains in quality-adjusted
life years were relatively small after incorporating quality
of life and risks of unintended eﬀects. The probabilistic
net health beneﬁt analyses demonstrated that it is not
possible to distinguish statistically between ranibizumab and
pegaptanib treatment as measured by QALYs, although the
beneﬁts of both active therapies are greater than treatment
with usual care.
The analysis suggests that in the case of nonocular hem-
orrhage as an example, that the net beneﬁt of treatments is
dependent on the incidence of the unintended consequence
and when the relative rates of unintended consequences
change, the net health beneﬁt changes as well.
There are several limitations. First, the validity of the
model and results are limited to that of the input data and
assumptions. While the intended eﬀects were estimated with
precision in the registration trials, only a small number
of unintended eﬀects were observed leading to higher
uncertainty in these eﬀects. As well, there are theoretical
concerns about QALYs that may reduce their validity [34,
35]. Despite those concerns, QALYs have many useful
characteristics including that they are straightforward toJournal of Ophthalmology 7
Table 6: Characteristics of study populations at baseline.
Pegaptanib1 0.3mg
(n = 295)
Pegaptanib1
UC (n = 296)
Ranibizumab2
(n = 379)
Ranibizumab2
UC (n = 381)
Sex, no(%)
Male 133 (45) 120 (40) 163 (43) 143 (38)
Female 164 (55) 178 (60) 217 (57) 238 (62)
Race, no(%)
White 283 (96) 284 (95) 268 (97) 371 (97)
Other 12 (4) 14 (5) 12 (3) 10 (3)
Age, no(%)
50–64 19 (6) 21 (7) 30 (8) 19 (5)
65–74 86 (29) 94 (32) 104 (27) 102 (27)
75–84 155 (53) 160 (54) 188 (50) 206 (54)
≥85 35 (12) 23 (8) 57 (15) 54 (14)
Mean 76.6 77.3
Range 52–93 53–95
LC, no(%)
PC 72 (24) 76 (26) 135 (36) 141 (37)
MC 111 (38) 102 (34) 96 (25) 89 (23)
OC 112 (38) 120 (40) 149 (39) 151 (40)
Mean LS 3.7 4.2 3.5 3.5
ETDRS VA Mean 56.2 52.7 51.3 50.6
≤20/200 45 (15) 45 (15) 63 (17) 78 (20)
20/40 > VA > 20/200 222 (76) 221 (75) 274 (72) 267 (71)
≥20/40 27 (9) 30 (10) 42 (11) 39 (9)
1From VISION Study [6] of pegaptanib, and safety and eﬃcacy summaries provided by Pﬁzer Inc.
2Pooled estimates from MARINA and ANCHOR [7, 8] studies of ranibizumab.
UC: usual care; LC: lesion composition; PC: predominantly classic; MC: minimally classic; OC: occult with no classic; LS: lesion size; ETDRS VA: early
Treatment of Diabetic Retinopathy Study visual acuity.
calculate and interpret and they have been incorporated
in many decision models. Second, because of a lack of
a head-to-head trial, only indirect comparisons of the
two VEGF inhibitors relative to usual care were possible
and third, data were extrapolated beyond the duration of
the registration trials. Although the VISION study was
two years in duration, patients crossed-over after the ﬁrst
year making the year two results challenging to interpret
with conﬁdence. We used the ﬁrst year of the two-year
long MARINA trial to make the duration comparable to
ANCHOR and VISION. Both these features were addressed
by making explicit assumptions and testing the impact
of alternative assumptions. Fourth, the source and quality
of utility data for intended and unintended eﬀects have
a large impact eﬀect on the results and interpretations.
For intended eﬀects, we incorporated preference values for
health states from a study of 72 patients with macular
degeneration of whom only 56 had evidence of neovascular
disease. The health states were not standardized and study
participants only provided utility estimates for the visual
acuity category in which they belonged. The actual numbers
of patients from whom mean health state utility estimates
were smaller [20, 36] than recommended [37]. Health
states were based upon best-corrected Snellen visual acuity
which is commonly used to track visual changes in clinical
practice. However, Snellen estimates correlate poorly with
visual acuities measured on logMAR charts [38], which were
used to monitor visual changes in the registration trials
[6–8]. As the health states (and utilities) were based on
visual acuity in the better-seeing eye we assumed that the
better-seeing eye was the treated eye (and that therefore all
model patients had developed neovascular disease in their
second eye). We therefore incorporated alternate, ETDRS-
based preference value estimates as a sensitivity analysis.
Fifth, a key component that is poorly understood is the
way in which the quality of life and utilities are aﬀected
when a person has more than one condition. In this case,
we assumed that the utilities were multiplicative, based on
anotherstudy[26].Otherstructuresofhowutilitiescombine
gave been suggested [39]. Finally, as utilities were only
available for visual acuity values for the better-seeing eye,
the generalizability of our model was limited to patients
withbilateralvisualproblemswherethetreatedeyemeasures
better visual acuity.8 Journal of Ophthalmology
5. Conclusion
The framework described here presents one method of
addressing Health Canada’s Progressive Licensing Project
goal of on-going review throughout the lifecycle of new
medications:multiplehealtheﬀectscanbeincorporated;dif-
ferent sources of data can be accommodated; uncertainty in
theinputdatacanbeexplicitlyincorporated;allassumptions
are made explicit and the impact of diﬀerent assumptions
can be tested; the time horizon can be extended to include
all relevant health eﬀects; and there is a natural link with
the model that can be used to assess the economic value
proposition.
Appendix
Input data were abstracted from the results of published
randomized trials of active comparator versus usual care [6–
8]. Baseline characteristics of the trial groups are presented
in Table 6. Usual care in the MARINA Study, examining the
safety and eﬃcacy of ranibizumab for NV-AMD patients
with OC or MC lesions, was sham treatment [8]; in the
ANCHOR Study, focusing on patients with PC lesions,
usual care was either PDT with verteporﬁn at the discretion
of the treating investigator or sham therapy [7]. Usual
care in the VISION Trial of pegaptanib consisted of sham
treatment for patients with OC and MC lesions or PDT
with verteporﬁn at the direction of the treating investigator
for those with PC lesions [6]. To allow incorporation
of the data into the net beneﬁt decision model, the
0.5mg treatment groups were combined from ANCHOR
and MARINA, and the usual care groups from MARINA,
ANCHOR, and VISION were pooled. The treatment eﬀect
(relative diﬀerences between usual care and treatment in
each trial) was maintained by applying the relative risks
of experiencing intended and unintended eﬀects to the
pooled data, to determine the estimates of intended and
unintended eﬀect rates for the pegaptanib and ranibizumab
groups.
Intended and unintended eﬀects were considered for
the indicated doses only: 0.3mg for pegaptanib, and 0.5mg
for ranibizumab. Intended eﬀects were quantiﬁed using the
distribution of changes in visual acuity over one year, with
baseline visual acuity distributions for all treatment groups
taken from the VISION Study.
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